At a glance
ClinicalIndex Comparison RecordN/ACompleted· 129 enrolled
Drug / intervention
NOWDx COVID-19 Testdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NOWDx Test for the Detection of Antibodies to COVID-19
In Brief
A clinical study evaluating NOWDx COVID-19 Test for COVID-19 and 2 related conditions. Completed, enrolled 129 participants across 3 sites.
Detailed Summary
This study is designed to compare the performance of the NOWDx COVID-19 Test to an emergency use authorized PCR test result. The intent is to show the rapid test device is comparable to a currently marketed device. The NOWDx COVID-19 Test is an in vitro lateral flow immunoassay intended for qualitative detection of total antibodies to SARS-CoV-2 in human whole blood (venous and fingerstick).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19, SARS-CoV-2, Coronavirus
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartSep 2020
First PostedDec 2020
Primary CompletionDec 2020
TodayJul 2026
First PostedDec 30, 2020
Enrollment StartSep 1, 2020
Primary CompletionDec 31, 2020
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 5.5 years ago
Interventions
NOWDx COVID-19 Testdevice
The investigational device is the NOWDx COVID-19 Test.